Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Anthony G. Quinn purchased 8,989 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were bought at an average cost of $6.56 per share, with a total value of $58,967.84. Following the transaction, the chief executive officer now directly owns 304,135 shares of the company’s stock, valued at approximately $1,995,125.60. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
AGLE stock traded down $0.06 on Friday, hitting $6.71. 14,537 shares of the company were exchanged, compared to its average volume of 179,774. Aeglea Bio Therapeutics Inc has a twelve month low of $6.31 and a twelve month high of $12.00. The firm has a market capitalization of $193.57 million, a price-to-earnings ratio of -3.15 and a beta of 0.89.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Sell-side analysts anticipate that Aeglea Bio Therapeutics Inc will post -2.19 earnings per share for the current fiscal year.
Several equities analysts recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Aeglea Bio Therapeutics in a research report on Thursday, March 21st. They set an “overweight” rating and a $14.00 price target for the company. ValuEngine lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 9th. Finally, HC Wainwright assumed coverage on shares of Aeglea Bio Therapeutics in a research report on Tuesday. They set a “buy” rating and a $20.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $16.00.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Further Reading: Forex
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.